Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MenACWY-CRM197 with Routine Infant Vaccinations
NCT00806195Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Primary completion
- Mar 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal infection (2 arms), sponsored by Novartis. Primary endpoint: Percentages of Subjects With At Least One Severe Systemic Reaction After Any Vaccination. Started Dec 2008; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT00806195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806195.